The aforementioned studies propose periodontal ligament MSC-CM as a new pharmacologic tool for managing multiple sclerosis through a remarked expression of anti-inflammatory cytokines (IL-10, TGF-β) [175, 176] and antiapoptotic cytokine (Bcl2) [170, 176] and subsequent suppression of proinflammatory mediators (IL-4, IL-17, IFN-γ, TNF-α, IL-6, and IL-1β) [175, 176], proapoptotic markers (Bax and cleaved caspase-3) [170, 175, 176], p53, STAT1 [175], cleaved caspase-1 [192], and oxidative stress markers (SOD-1, iNOS, and COX-2) [170, 176]. The gene discussed is NOS2; the disease is multiple sclerosis.